Deaths In Esperion's Long-Term Bempedoic Acid Trial Spur Fears Of Commercial Delay
On top of concerns about safety, which could present regulatory hurdles, bempedoic acid is likely to face a tougher competitive environment after the decline in PCSK9 inhibitor pricing.
You may also be interested in...
Keeping Track Of Non-Oncology Review and Approval News: Erectile Dysfunction, Parkinson's, Cholesterol
The latest non-oncology drug development news and highlights from our US FDA Performance Tracker.
Final Phase III study for pivotal package of cholesterol drug bempedoic acid shows LDL-lowering efficacy and a clean safety profile, paving the way for filings in the first half of 2019.
Esperion is emphasizing the low list and net price of its oral bempedoic acid for cholesterol reduction, relative to the injectable PCSCK9 inhibitors, but still significantly higher than other oral cholesterol-lowering drugs.